Presented by RGA
GLP‑1 therapies are emerging as a critical area of focus for both population health and insurance risk. In this roundtable, RGA’s biometric experts examine the latest research and early evidence, unpacking what these therapies could mean in an evolving and uncertain landscape.
Key takeaways:
Presented by RGA
New results from the highly anticipated NHS-Galleri study show that the trial did not meet its primary endpoint of achieving a statistically significant reduction in combined Stage III and IV cancer diagnoses. While secondary findings offer more encouraging signals, particularly in detecting aggressive cancers, they warrant careful interpretation. RGA unpacks what these results mean for insurers today and what to watch as the landscape continues to evolve.
Presented by RGA
Long marked by late diagnosis and limited treatment, Alzheimer’s disease is now at a pivotal turning point. As breakthroughs emerge in early detection, prevention, and disease‑modifying therapies, could the global trajectory of Alzheimer’s finally be changing, and what might that mean for the decades ahead?
Presented by Oliver Wyman
Global dynamics have accelerated in 2026. Fragmenting geopolitics, more interventionist industrial policies, and an increased focus on digital sovereignty are forcing insurance leaders to rethink where to deploy capital, talent, and technology.
Meanwhile, private capital is structurally reshaping insurance through run-off deals, consolidation, and asset-intensive platforms.
Presented by bolttech
As digital transformation reshapes global finance, embedded insurance is becoming a new growth engine for banks and fintechs. With trusted customer relationships, rich data, and millions of daily interactions, financial institutions are uniquely positioned to deliver protection products that enhance loyalty, increase lifetime value, and open new revenue streams.
Presented by Kyobo Life Insurance Company
Last year, Kyobo Life placed an even greater emphasis on the customer. The ‘Balanced Protection’ project was launched to provide optimal coverage across every stage of the customer’s lifecycle, as well as utilized insights gained from the ‘VOC (Voice of Customer)’ program to improve their products and services, and established a deducated healthcare subsidiary, ‘Kyobo Dasom Care’, to offer differenciated health management services.
Brittainy Rivers, COO & VP, Client Delivery, TAI, an RGA Company
Hector Martinez, Head of Insurance, US Segment, John Hancock
Virginie Guinée, Group Head of Pricing - Life & Health Group Benefits, AXA GIE
Presented by RGA
Behavioral science techniques can significantly improve customer understanding of life insurance products and help reverse declining ownership rates, with RGA research offering practical strategies insurers can implement today.
